ArticleInfection and immunity2014
Distinct regions of NLRP1B are required to respond to anthrax lethal toxin and metabolic inhibition.
Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Gasdermin-Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer.Cancer science · 2026Review
- Diverse autoinhibitory mechanisms of FIIND-containing proteins: Insight into regulation of NLRP1 and CARD8 inflammasome.PLoS pathogens · 2025Article
- Inflammasomes and their role in PANoptosomes.Current opinion in immunology · 2024Review
- Activation of the NLRP1B inflammasome by caspase-8.Communications biology · 2024Article
- The NLR gene family: from discovery to present day.Nature reviews. Immunology · 2023Review
- NLRP1 Inflammasomes: A Potential Target for the Treatment of Several Types of Brain Injury.Frontiers in immunology · 2022Review
- Metabolic regulators of enigmatic inflammasomes in autoimmune diseases and crosstalk with innate immune receptors.Immunology · 2021Review
- The NLRP1 and CARD8 inflammasomes.Immunological reviews · 2020Review
- The NLRP1 inflammasome: new mechanistic insights and unresolved mysteries.Current opinion in immunology · 2019Review
- Functional degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes.Science (New York, N.Y.) · 2019Article
- ThreemBio · 2019Article
- Inflammasomes in livestock and wildlife: Insights into the intersection of pathogens and natural host species.Veterinary immunology and immunopathology · 2018Review
- Listeria monocytogenes and Shigella flexneri Activate the NLRP1B Inflammasome.Infection and immunity · 2017Article
- Functional and Evolutionary Analyses Identify Proteolysis as a General Mechanism for NLRP1 Inflammasome Activation.PLoS pathogens · 2016Article
- Deviant Behavior: Tick-Borne Pathogens and Inflammasome Signaling.Veterinary sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pattern recognition receptors monitor for signs of infection or cellular dysfunction and respond to these events by initiating an immune response. NLRP1B is a receptor that upon activation recruits multiple copies of procaspase-1, which promotes cytokine processing and a proinflammatory form of cell death termed pyroptosis. NLRP1B detects anthrax lethal toxin when the toxin cleaves an amino-terminal fragment from the protein. In addition, NLRP1B is activated when cells are deprived of glucose or treated with metabolic inhibitors, but the mechanism by which the resulting reduction in cytosolic ATP is sensed by NLRP1B is unknown. Here, we addressed whether these two activating signals of NLRP1B converge on a common sensing system. We show that an NLRP1B mutant lacking the amino-terminal region exhibits some spontaneous activity and fails to be further activated by lethal toxin. This mutant was still activated in cells depleted of ATP, however, indicating that the amino-terminal region is not the sole sensing domain of NLRP1B. Mutagenesis of the leucine-rich repeat domain of NLRP1B provided evidence that this domain is involved in autoinhibition of the receptor, but none of the mutants tested was specifically defective at sensing activating signals. Comparison of two alleles of NLRP1B that differed in their response to metabolic inhibitors, but not to lethal toxin, led to the finding that a repeated sequence in the function to find domain (FIIND) that arose from exon duplication facilitated detection of ATP depletion. These results suggest that distinct regions of NLRP1B detect activating signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.